• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与低危妊娠滋养细胞肿瘤患者 hCG 缓解时间相关的预后因素。

Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia.

机构信息

Department of Gynecology and Obstetrics, Botucatu Medical School, UNESP-Sao Paulo State University, Botucatu, SP, Brazil.

出版信息

Gynecol Oncol. 2013 Aug;130(2):312-6. doi: 10.1016/j.ygyno.2013.05.017. Epub 2013 May 23.

DOI:10.1016/j.ygyno.2013.05.017
PMID:23707672
Abstract

OBJECTIVE

The purpose of this study was to identify the clinical factors associated with time to hCG remission among women with low-risk postmolar GTN.

METHODS

This study included a non-concurrent cohort of 328 patients diagnosed with low-risk postmolar GTN according to FIGO 2002 criteria. Associations of time to hCG remission with history of prior mole, molar histology, time to persistence, use of D&C at persistence, presence of metastatic disease, FIGO score, hCG values at persistence, type of first line therapy and use of multiagent chemotherapy were investigated with both univariate and multivariate analyses.

RESULTS

Overall median time to remission was 46 days. Ten percent of the patients required multi-agent chemotherapy to achieve hCG remission. Multivariate analysis incorporating the variables significant on univariate analysis confirmed that complete molar histology (HR 1.45), metastatic disease (HR 1.66), use of multi-agent therapy (HR 2.00) and FIGO score (HR 1.82) were associated with longer time to remission. There was a linear relationship between FIGO score and time to hCG remission. Each 1-point increment in FIGO score was associated with an average 17-day increase in hCG remission time (95% CI: 12.5-21.6).

CONCLUSIONS

Complete mole histology prior to GTN, presence of metastatic disease, use of multi-agent therapy and higher FIGO score were independent factors associated with longer time to hCG remission in low-risk GTN. Identifying the prognostic factors associated with time to remission and effective counseling may help improve treatment planning and reduce anxiety in patients and their families.

摘要

目的

本研究旨在确定低危绒癌患者血 hCG 转阴时间的相关临床因素。

方法

本研究纳入了根据 FIGO 2002 标准诊断为低危绒癌的 328 例患者,进行了一项非同期队列研究。采用单因素和多因素分析方法,探讨了既往葡萄胎史、绒癌组织学类型、持续时间、持续时间行清宫术、是否存在转移病灶、FIGO 评分、持续时间 hCG 值、一线治疗方案类型及是否使用联合化疗与 hCG 转阴时间的相关性。

结果

总体中位转阴时间为 46 天。10%的患者需要联合化疗才能使 hCG 转阴。多因素分析纳入单因素分析有统计学意义的变量,证实完全性葡萄胎组织学(HR 1.45)、转移病灶(HR 1.66)、使用联合化疗(HR 2.00)和 FIGO 评分(HR 1.82)与更长的转阴时间相关。FIGO 评分与 hCG 转阴时间呈线性关系。FIGO 评分每增加 1 分,hCG 转阴时间平均增加 17 天(95%CI:12.5-21.6)。

结论

绒癌前有完全性葡萄胎病史、存在转移病灶、使用联合化疗及 FIGO 评分较高是低危绒癌患者 hCG 转阴时间延长的独立影响因素。识别与转阴时间相关的预后因素,并进行有效的咨询,可能有助于改善治疗计划,减轻患者及其家属的焦虑。

相似文献

1
Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia.与低危妊娠滋养细胞肿瘤患者 hCG 缓解时间相关的预后因素。
Gynecol Oncol. 2013 Aug;130(2):312-6. doi: 10.1016/j.ygyno.2013.05.017. Epub 2013 May 23.
2
Gestational trophoblastic neoplasia after achieving a nondetectable serum human chorionic gonadotrophin level.达到血清人绒毛膜促性腺激素水平不可检测后发生的妊娠滋养细胞肿瘤。
BJOG. 2014 Oct;121(11):1415-9. doi: 10.1111/1471-0528.12742. Epub 2014 Mar 28.
3
[Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].[单药甲氨蝶呤一线化疗对低危妊娠滋养细胞肿瘤的疗效及其影响因素]
Zhonghua Yi Xue Za Zhi. 2005 Aug 10;85(30):2109-12.
4
Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?对于完全性葡萄胎清宫术后四周人绒毛膜促性腺激素水平超过20,000 IU/L的情况,是否构成妊娠滋养细胞肿瘤化疗的指征?
Eur J Obstet Gynecol Reprod Biol. 2018 Apr;223:50-55. doi: 10.1016/j.ejogrb.2018.02.001. Epub 2018 Feb 15.
5
Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study.葡萄胎随访环境对葡萄胎后妊娠滋养细胞肿瘤结局的影响:一项队列研究
J Reprod Med. 2012 Jul-Aug;57(7-8):305-9.
6
Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.在 hCG 缓解前使用激素避孕药不会增加完全性葡萄胎后发生妊娠滋养细胞肿瘤的风险:一项历史数据库回顾。
BJOG. 2016 Jul;123(8):1330-5. doi: 10.1111/1471-0528.13617. Epub 2015 Oct 7.
7
Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.评估甲氨蝶呤治疗低危葡萄胎后妊娠滋养细胞肿瘤患者的疗效。
Gynecol Oncol. 2009 Feb;112(2):353-7. doi: 10.1016/j.ygyno.2008.11.003. Epub 2008 Dec 6.
8
Gestational trophoblastic neoplasia after spontaneous human chorionic gonadotropin normalization following molar pregnancy evacuation.葡萄胎排空后人绒毛膜促性腺激素自然恢复正常后的妊娠滋养细胞肿瘤
Gynecol Oncol. 2015 Nov;139(2):283-7. doi: 10.1016/j.ygyno.2015.09.012. Epub 2015 Sep 14.
9
Human chorionic gonadotrophin regression rate as a predictive factor of postmolar gestational trophoblastic neoplasm in high-risk hydatidiform mole: a case-control study.人绒毛膜促性腺激素下降率作为高危型葡萄胎绒毛膜滋养细胞肿瘤的预测因素:一项病例对照研究。
Eur J Obstet Gynecol Reprod Biol. 2012 Jan;160(1):100-5. doi: 10.1016/j.ejogrb.2011.10.003. Epub 2011 Nov 3.
10
Postmolar gestational trophoblastic neoplasia: beyond the traditional risk factors.磨牙后妊娠滋养细胞肿瘤:超越传统危险因素
Fertil Steril. 2015 Sep;104(3):649-54. doi: 10.1016/j.fertnstert.2015.06.001. Epub 2015 Jun 19.

引用本文的文献

1
Factors influencing serum hCG negativization timing in gestational trophoblastic neoplasia.影响妊娠滋养细胞肿瘤血清人绒毛膜促性腺激素转阴时间的因素。
Am J Cancer Res. 2025 Jan 15;15(1):331-347. doi: 10.62347/HFRL7722. eCollection 2025.
2
Geographical Health District and Distance Traveled Influence on Clinical Status at Admission of Patients with Gestational Trophoblastic Disease.地理卫生区域和旅行距离对妊娠滋养细胞疾病患者入院时临床状况的影响。
Rev Bras Ginecol Obstet. 2023 Jul;45(7):e384-e392. doi: 10.1055/s-0043-1772179. Epub 2023 Aug 18.
3
Role of Salvage Surgery in Gestational Trophoblastic Neoplasia: a Regional Cancer Centre Experience.
挽救性手术在妊娠滋养细胞肿瘤中的作用:一家地区癌症中心的经验
Indian J Surg Oncol. 2022 Dec;13(4):702-706. doi: 10.1007/s13193-022-01644-1. Epub 2022 Sep 16.
4
Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis.随访葡萄胎妊娠后妊娠滋养细胞肿瘤:成本效益分析。
Am J Obstet Gynecol. 2021 Nov;225(5):513.e1-513.e19. doi: 10.1016/j.ajog.2021.05.031. Epub 2021 May 29.
5
Incidence and outcome of gestational trophoblastic disease in lower Egypt.埃及低地妊娠滋养细胞疾病的发病情况和结局。
Afr Health Sci. 2020 Mar;20(1):73-82. doi: 10.4314/ahs.v20i1.12.
6
Management and prognostic analysis of patients with gestational trophoblastic neoplasia (GTN) in FIGO stage IV and its special type.FIGO IV期妊娠滋养细胞肿瘤(GTN)及其特殊类型患者的管理与预后分析
Clin Exp Metastasis. 2021 Feb;38(1):47-59. doi: 10.1007/s10585-020-10064-w. Epub 2020 Nov 20.
7
Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis.对于年龄至少 40 岁的患者,全子宫切除术与子宫排空术预防葡萄胎后妊娠滋养细胞肿瘤:系统评价和荟萃分析。
BMC Cancer. 2019 Jan 7;19(1):13. doi: 10.1186/s12885-018-5168-x.
8
Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide.二线化疗方案治疗低危型妊娠滋养细胞肿瘤患者的疗效:5 天甲氨蝶呤联合 5 天依托泊苷。
J Gynecol Oncol. 2018 Nov;29(6):e89. doi: 10.3802/jgo.2018.29.e89.
9
Uterine artery Doppler flow velocimetry parameters for predicting gestational trophoblastic neoplasia after complete hydatidiform mole, a prospective cohort study.完全性葡萄胎后预测妊娠滋养细胞肿瘤的子宫动脉多普勒血流测速参数:一项前瞻性队列研究
Clinics (Sao Paulo). 2017 May;72(5):284-288. doi: 10.6061/clinics/2017(05)05.